Literature DB >> 29439890

Brugada-Type Pattern on Electrocardiogram Associated with High-Dose Loperamide Abuse.

Christie Sun1, Jessica A Brice2, Richard F Clark1.   

Abstract

BACKGROUND: Loperamide has been increasing in popularity recently for its effects separate from treatment of diarrhea. In large doses or in combination with other agents, it can lead to desirable effects in the central nervous system. However, cardiotoxicity has been reported with its abuse. CASE REPORT: A 49-year-old male who had been chronically abusing loperamide was found to have Brugada-like changes on his electrocardiogram (ECG). He had no other clinical symptoms associated with Brugada syndrome and did not have similar findings on previous ECGs. After abstaining from further loperamide use during hospitalization, this pattern slowly resolved without clinically significant dysrthymias. WHY SHOULD AN EMERGENCY PHYSICIAN BE AWARE OF THIS?: A patient with a history of loperamide abuse is at risk for cardiotoxicity. While other dysrhythmias are reported more commonly with loperamide abuse, Brugada-like ECG changes can occur and warrant appropriate consultation and prompt follow-up.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Brugada; drug abuse; dysrhythmia; loperamide

Mesh:

Substances:

Year:  2018        PMID: 29439890     DOI: 10.1016/j.jemermed.2017.12.040

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  2 in total

1.  Arrhythmia Assessment in Heterotypic Human Cardiac Myocyte-Fibroblast Microtissues.

Authors:  Celinda M Kofron; Bum-Rak Choi; Kareen L K Coulombe
Journal:  Methods Mol Biol       Date:  2022

2.  A predictive in vitro risk assessment platform for pro-arrhythmic toxicity using human 3D cardiac microtissues.

Authors:  Celinda M Kofron; Tae Yun Kim; Bum-Rak Choi; Kareen L K Coulombe; Fabiola Munarin; Arvin H Soepriatna; Rajeev J Kant; Ulrike Mende
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.